Significant decrease of SMAD4 protein in DBA iPSCs. by Jingping Ge (636557)

“…A) Slight decrease of mRNA level of <i>SMAD4</i> in the DBA iPSCs with <i>RPS19</i> or <i>RPL5</i> mutations. …”

Hyperalgesia was assessed by a decrease in paw withdrawal threshold (PWT_50%) in a model of mild heat injury (MHI). by Manuel P. Pereira (417488)

S1 Data - by Emma Nixon (11772946)

Subjects:

Fig 3 - by Emma Nixon (11772946)

Subjects:

Daily change in bodyweight from baseline over the course of the study, where day 0 is when catheters and ISF probes were placed, and day 3 is the day of processing. by Emma Nixon (11772946)

Subjects:

Supplementary Material for: Decreasing Attacks and Improving Quality of Life through a Systematic Management Program for Patients with Hereditary Angioedema by Nunes F.L. (10223465)

A R13A point mutation in C4 attenuates CLCuMuV infection. by Asigul Ismayil (5698946)

“…<b>(C)</b> The mutant CLCuMuV carrying C4^R13A (CLCuMuV-C4^R13A), which contains a R13A mutation in <i>C4</i>, showed the decreased viral symptom compared to wild type CLCuMuV. …”

Depletion of Atg5 inhibits IDN5706-induced autophagy, but not EDEM1 degradation. by Viviana A. Cavieres (500139)

Total plasma cortisol concentration over time following intramuscular administration of either 0.1 mL saline, 0.4 mg/kg meloxicam, 2.2 mg/kg flunixin or 3.0 mg/kg ketoprofen in 6-d... by Emma Nixon (11772946)

Subjects:

Functional linear modeling (FLM) of activity data following intramuscular administration of either 0.1 mL saline, 0.4 mg/kg meloxicam, 2.2 mg/kg flunixin or 3.0 mg/kg ketoprofen in... by Emma Nixon (11772946)

Subjects:

Total ISF PGE2 concentration over time (accounting for ISF probe lag time) following intramuscular administration of either 0.1 mL saline, 0.4 mg/kg meloxicam, 2.2 mg/kg flunixin o... by Emma Nixon (11772946)

Subjects:

Fig 5 - by Hannah N. Marmor (14046394)

Inadequate riparian zone use directly decreases water quality of a low-order urban stream in southern Brazil by Enzo Luigi Crisigiovanni (8709570)

The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial by Ma Somsouk (283498)

“…<div><p>The anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis. …”

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)